Forward-looking statement

NOHO, INC. HOLDS SHAREHOLDER CALL AND PROVIDES GREEN ENERGY UPDATE

Tuesday, July 27, 2021 - 1:00pm

The Company is currently engaged in preliminary discussions with a green energy technology company, which holds patents in the area of distributed Renewable Energy Platforms (DREP).

Key Points: 
  • The Company is currently engaged in preliminary discussions with a green energy technology company, which holds patents in the area of distributed Renewable Energy Platforms (DREP).
  • The firm is in revenue and seeks additional capital to build a marketing and sales campaign in exchange for significant equity.
  • For additional information and product updates, please follow us at www.nohoshot.com and follow NOHO on Twitter at www.twitter.com/nohodrink
    Cautionary Note Regarding Forward-Looking Statements.
  • The words may, would, will, expect, estimate, can, believe,potential and similar expressions and variations thereof are intended to identify forward-lookingstatements.

OptimizeRx Sets Second Quarter Fiscal 2021 Conference Call for Wednesday, August 4 at 4:30 p.m. ET

Tuesday, July 27, 2021 - 1:00pm

Connecting over half of healthcare providers in theU.S.and millions of patients through a proprietary network, theOptimizeRxdigital health platform helps patients afford and stay on medications.

Key Points: 
  • Connecting over half of healthcare providers in theU.S.and millions of patients through a proprietary network, theOptimizeRxdigital health platform helps patients afford and stay on medications.
  • The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
  • The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

Nanox to Announce Second Quarter 2021 Financial and Operating Results on Tuesday, August 10, 2021

Tuesday, July 27, 2021 - 1:00pm

Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all.

Key Points: 
  • Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all.
  • This press release may contain forward-looking statements that are subject to risks and uncertainties.
  • All statements that are not historical facts contained in this press release are forward-looking statements.
  • Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox's expectations.

Antibe Therapeutics Provides July 2021 Corporate Update

Tuesday, July 27, 2021 - 12:00pm

Antibe is taking a comprehensive approach to maximizing the likelihood of a successful Phase III program outcome.

Key Points: 
  • Antibe is taking a comprehensive approach to maximizing the likelihood of a successful Phase III program outcome.
  • The program also combines several state-of-the-art aspects, including the hiring of leading providers of bioanalytic, quality control and data management services.
  • The latter will enable us to track and manage screening and enrollment in real-time, ensuring that the subject population matches trial criteria.
  • Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

iSpecimen to Report Second Quarter 2021 Results on August 10, 2021

Tuesday, July 27, 2021 - 12:00pm

Participants must use the following code to access the replay of the call: 13721607.

Key Points: 
  • Participants must use the following code to access the replay of the call: 13721607.
  • An archived version of the webcast will also be available on iSpecimen's Investor Relations site: https://ispecimen.irpass.com/ .
  • iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery.
  • Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words.

Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021

Tuesday, July 27, 2021 - 11:00am

Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.

Key Points: 
  • Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.
  • The antibody tests can detect antibodies that are generated both from infection by the virus and from the vaccines.
  • Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors.
  • Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.

Hyloris to Report 2021 Half-Year Results on 4 August 2021

Tuesday, July 27, 2021 - 6:00am

The webcast may be accessed on the Events page of the companys website or by clicking here .

Key Points: 
  • The webcast may be accessed on the Events page of the companys website or by clicking here .
  • Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.
  • Hyloris has built a broad, patented portfolio of 13 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives.
  • The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Maritime Resources Intersects 39.98 gpt Gold over 2.05 Metres at Hammerdown, Including 140.16 gpt Au over 0.20 Metres

Monday, July 26, 2021 - 11:00am

In accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects, Larry Pilgrim, P.Geo.

Key Points: 
  • In accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects, Larry Pilgrim, P.Geo.
  • Exploration Manager, is the Qualified Person for the Company and has reviewed and approved the technical and scientific content of this news release.
  • Certain of the statements made and information contained herein is "forward-looking information" within the meaning of National Instrument 51-102 - Continuous Disclosure Obligations.
  • Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "intends", "indicates" "plans" and similar expressions.

Minim Announces Launch of Proposed Public Offering of Common Stock

Monday, July 26, 2021 - 9:06pm

MANCHESTER, NH, July 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Minim, Inc. (NASDAQ: MINM) (the Company) today announces the launch of the Companys proposed public offering of $25 millionpursuant to a registration statement filed with the Securities and Exchange Commission (SEC).

Key Points: 
  • MANCHESTER, NH, July 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Minim, Inc. (NASDAQ: MINM) (the Company) today announces the launch of the Companys proposed public offering of $25 millionpursuant to a registration statement filed with the Securities and Exchange Commission (SEC).
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • B. Riley Securities is acting as the sole book-running manager for the proposed offering.
  • Minim cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.

Mountain Crest Acquisition Corp. IV Announces that Common Stock and Rights to Commence Separate Trading on or about July 28, 2021

Monday, July 26, 2021 - 9:05pm

The common stock and rights will trade on the NASDAQ Capital Market ("NASDAQ") under the symbols MCAF and MCAFR, respectively.

Key Points: 
  • The common stock and rights will trade on the NASDAQ Capital Market ("NASDAQ") under the symbols MCAF and MCAFR, respectively.
  • After separation, the common stock and rights may be recombined to create units.
  • About Mountain Crest Acquisition Corp. IV
    Mountain Crest Acquisition Corp. IV is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
  • Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.